- ISIN
- US2300311063
- CUSIP
- 230031106
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jan 8, 2021
Highlights
- Market Cap
- $1.01B
- Enterprise Value
- $942.08M
- EPS (TTM)
- -$5.61
- Gross Profit (TTM)
- -$79.00K
- EBITDA (TTM)
- -$240.43M
- Year Range
- $5.68 - $19.43
- Target Price
- $31.14
- ROA (TTM)
- -54.85%
- ROE (TTM)
- -60.36%
- Avg. Volume (1M)
- 600K
- Avg. Volume Value (1M)
- $10.55M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
CGEM Performance Chart
Cullinan Oncology, Inc. (CGEM) is up 59.4% since the beginning of the year. At $17 per share, CGEM is trading 15.1% below its 52-week high of $19. Investors who bought $1,000 worth of CGEM shares 5 years ago would now be looking at an investment worth $720.
Loading charts...
Compare this symbol against anything
Returns By Period
Cullinan Oncology, Inc. (CGEM) has returned 59.42% so far this year and 115.12% over the past 12 months.
Cullinan Oncology, Inc.
- 1D
- -5.82%
- 1M
- -6.41%
- 6M
- 37.96%
- YTD
- 59.42%
- 1Y
- 115.12%
- 3Y*
- 16.71%
- 5Y*
- -6.37%
- 10Y*
- —
- ALL TIME*
- -15.47%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
CGEM Monthly Returns History
Based on dividend-adjusted daily data since Jan 8, 2021, CGEM's average daily return is +0.03%, while the average monthly return is -0.03%.
Historically, 40% of months were positive and 60% were negative. The best month was Apr 2024 with a return of +58.5%, while the worst month was Mar 2022 at -27.0%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 7 months.
On a daily basis, CGEM closed higher 48% of trading days. The best single day was Nov 24, 2025 with a return of +36.5%, while the worst single day was Jan 8, 2021 at -28.8%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 15.56% | 29.60% | -8.32% | -8.16% | 25.98% | 10.77% | -9.39% | 59.42% | |||||
| 2025 | -13.30% | -19.60% | -10.84% | 9.38% | 4.41% | -12.90% | 3.19% | -2.96% | -21.35% | 46.04% | 31.29% | -8.97% | -15.02% |
| 2024 | 48.58% | 21.99% | -7.74% | 58.51% | -13.00% | -25.79% | 10.95% | 1.29% | -14.59% | -7.11% | -13.50% | -9.44% | 19.53% |
| 2023 | 10.33% | -3.01% | -9.39% | -4.89% | 5.65% | 4.67% | -1.58% | -2.27% | -12.56% | 3.09% | -12.22% | 24.42% | -3.41% |
| 2022 | -12.64% | 6.38% | -26.99% | -6.30% | 8.97% | 19.93% | 5.38% | -0.22% | -4.90% | 2.50% | -5.40% | -15.12% | -31.63% |
| 2021 | -9.50% | 6.34% | 3.09% | -22.10% | -8.41% | -13.39% | -10.95% | 23.07% | -20.02% | -1.55% | -18.99% | -14.28% | -63.26% |
Benchmark Metrics
Cullinan Oncology, Inc. has an annualized alpha of -9.03%, beta of 1.27, and R2 of 0.09 versus S&P 500 Index. Calculated based on daily prices since January 08, 2021.
- This stock participated in 85.17% of S&P 500 Index downside but only -9.61% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.09 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -9.03%
- Beta
- 1.27
- R²
- 0.09
- Upside Capture
- -9.61%
- Downside Capture
- 85.17%
Return for Risk
Risk / Return Rank
CGEM ranks 86 for risk / return — above 86% of stocks peers on PortfoliosLab. Its historical combined result is among the stronger results in the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Cullinan Oncology, Inc. (CGEM) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CGEM | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.01 | ||
| Sortino ratioReturn per unit of downside risk | +0.43 | ||
| Omega ratioGain probability vs. loss probability | 1.27 | 1.25 | +0.02 |
| Calmar ratioReturn relative to maximum drawdown | 3.79 | 2.00 | +1.79 |
| Martin ratioReturn relative to average drawdown | 8.35 | 8.49 | -0.14 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Cullinan Oncology, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Cullinan Oncology, Inc. was 89.24%, occurring on Oct 2, 2025. The portfolio has not yet recovered.
The current Cullinan Oncology, Inc. drawdown is 69.11%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-89.24%Oct 2025 | 4y 6mo | — | 5y 4moMar 2021 - now | — |
-33.33%Jan 2021 | 3d | 1mo 6d | 1mo 9dJan 2021 - Feb 2021 | — |
-17.29%Mar 2021 | 1d | 6d | 7dMar 2021 - Mar 2021 | — |
-11.61%Feb 2021 | 4d | 3d | 7dFeb 2021 - Mar 2021 | — |
-0.23%Feb 2021 | 1d | 1d | 1dFeb 2021 - Feb 2021 | — |
Drawdown Indicators
| CGEM | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -89.24% | -56.78% | -32.46% |
Max Drawdown (1Y)Largest decline over 1 year | -29.79% | -9.10% | -20.69% |
Max Drawdown (3Y)Largest decline over 3 years | -80.41% | -18.90% | -61.51% |
Max Drawdown (5Y)Largest decline over 5 years | -80.63% | -25.43% | -55.20% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -69.11% | -1.58% | -67.53% |
Average DrawdownAverage peak-to-trough decline | -70.71% | -10.70% | -60.01% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 13.51% | 2.14% | +11.37% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Cullinan Oncology, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Cullinan Oncology, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with CGEM
Add Cullinan Oncology, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with CGEM